
Join to View Full Profile
800 Biesterfield Rd.Cancer Institute Bld. #5, Ste. 210Elk Grove Village, IL 60007
Phone+1 847-437-3312
Fax+1 847-981-5917
Dr. Gordon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1983 - 1986
- Johns Hopkins UniversityResidency, Internal Medicine, 1980 - 1983
- Johns Hopkins University School of MedicineClass of 1977
Certifications & Licensure
- IL State Medical License 1994 - 2026
- MD State Medical License 1983 - 2022
- FL State Medical License 2000 - 2005
- CT State Medical License 1995 - 1997
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer Start of enrollment: 2001 Jun 01
Publications & Presentations
PubMed
- 13 citationsActivity of the Gamma Secretase Inhibitor AL101 in Desmoid Tumors: A Case Report of 2 Adult CasesDavid Chan, Jason B. Kaplan, Gary Gordon, Jayesh Desai
Current Oncology. 2021-09-21 - 243 citationsVenetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyJohn F. Seymour, Shuo Ma, Danielle M. Brander, Michael Y. Choi, Jacqueline C. Barrientos
The Lancet. Oncology. 2017-02-01 - 576 citationsVenetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 studyStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Steven Coutre, John F. Seymour
The Lancet. Oncology. 2016-06-01
Press Mentions
- ODAC Recommends Approval of Epoetin Alfa BiosimilarMay 25th, 2017
- Veliparib Falls Short in Phase III NSCLC, TNBC TrialsApril 20th, 2017
- The 20-Year Journey Yielding a New Weapon Against CancerJanuary 10th, 2017
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: